Pancreatic cancer 3

Common Name(s)

Pancreatic cancer 3

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 3" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 3" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

http://www.pancan.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pancreatic cancer 3" returned 95 free, full-text research articles on human participants. First 3 results:

Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer.
 

Author(s): Wei Wang, Mei Zhang, Weimin Sun, Shanmin Yang, Ying Su, Hengshan Zhang, Chaomei Liu, Xinfeng Li, Ling Lin, Sunghee Kim, Paul Okunieff, Zhenhuan Zhang, Lurong Zhang

Journal:

 

Most human pancreatic cancer cells are resistant to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. However, the mechanisms by which pancreatic cancer cells utilize their extracellular molecules to counteract the proapoptotic signaling mediated ...

Last Updated: 8 Nov 2013

Go To URL
A novel regulatory mechanism of Pim-3 kinase stability and its involvement in pancreatic cancer progression.
 

Author(s): Fei Zhang, Bin Liu, Zhen Wang, Xian-Jun Yu, Quan-Xing Ni, Wen-Tao Yang, Naofumi Mukaida, Ying-Yi Li

Journal: Mol. Cancer Res.. 2013 Dec;11(12):1508-20.

 

Translationally controlled tumor protein (TCTP/TPT1) was identified from a yeast 2-hybrid screen and shown to interact with Pim-3, a member of the proto-oncogene Pim family with serine/threonine kinase activity. TCTP was aberrantly expressed in human pancreatic cancer cells and malignant ...

Last Updated: 19 Dec 2013

Go To URL
The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
 

Author(s): Elena Kurenova, Jianqun Liao, Di-Hua He, Darrell Hunt, Michael Yemma, Wiam Bshara, Mukund Seshadri, William G Cance

Journal: Oncotarget. 2013 Oct;4(10):1632-46.

 

Even with successful surgical resection and perioperative chemotherapy and radiation, pancreatic ductal adenocarcinoma (PDA) has a high incidence of recurrence. Tumor cell survival depends on activation of signaling pathways that suppress the apoptotic stimuli of invasion and metastasis. ...

Last Updated: 21 Oct 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pancreatic cancer 3" returned 6 free, full-text review articles on human participants. First 3 results:

Fish or long-chain (n-3) PUFA intake is not associated with pancreatic cancer risk in a meta-analysis and systematic review.
 

Author(s): Bo Qin, Pengcheng Xun, Ka He

Journal: J. Nutr.. 2012 Jun;142(6):1067-73.

 

Long-chain (n-3) PUFA (LC-PUFA) have been hypothesized to be beneficial in preventing pancreatic carcinogenesis, but the associations of fish or LC-PUFA intake with pancreatic cancer found in epidemiologic studies have been controversial and inconclusive. To estimate the overall association ...

Last Updated: 21 May 2012

Go To URL
Palliative care of pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
 

Author(s): Muhammad Wasif Saif

Journal:

 

Pancreatic cancer is one of the most fatal malignancies. Palliative care represents an important aspect of management in patients with pancreatic malignancy. Identifying and treating disease related symptoms are very important. As a physician taking care of these patients it is essential ...

Last Updated: 8 Jul 2011

Go To URL
Adjuvant Therapy of Pancreatic Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
 

Author(s): Charu Sharma, David Horowitz, John Chabot, Muhammad Wasif Saif

Journal:

 

Strong evidence exists for the use of adjuvant chemotherapy following surgical resection in pancreatic cancer, whereas the role of adjuvant chemoradiotherapy remains controversial. The optimal time to initiate adjuvant therapy has yet to be elucidated, but is usually started 2-10 ...

Last Updated: 8 Jul 2011

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
 

Status: Recruiting

Condition Summary: Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Ependymoblastoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Adult Pineal Gland Astrocytoma; Adult Solid Neoplasm; AIDS Related Immunoblastic Lymphoma; AIDS-Related Burkitt Lymphoma; AIDS-Related Diffuse Large Cell Lymphoma; AIDS-Related Diffuse Mixed Cell Lymphoma; AIDS-Related Diffuse Small Cleaved Cell Lymphoma; AIDS-Related Hodgkin Lymphoma; AIDS-Related Lymphoblastic Lymphoma; AIDS-Related Lymphoma; AIDS-Related Primary Central Nervous System Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Cutaneous B-Cell Non-Hodgkin Lymphoma; Extensive Stage Small Cell Lung Carcinoma; Extra-Adrenal Paraganglioma; Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Gastrin-Producing Neuroendocrine Tumor; Hepatic Complication; Hepatosplenic T-Cell Lymphoma; Intraocular Lymphoma; Lung Carcinoid Tumor; Lymphomatous Involvement of Non-Cutaneous Extranodal Site; Male Breast Carcinoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Gastrointestinal Neuroendocrine Tumor G1; Nasal Cavity Inverted Papilloma; Nodal Marginal Zone Lymphoma; Olfactory Neuroblastoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Adrenal Gland Pheochromocytoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Brain Neoplasm; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Colon Carcinoma; Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent Gastrointestinal Neuroendocrine Tumor G1; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Inverted Schneiderian Papilloma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Lip Basal Cell Carcinoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Melanoma; Recurrent Merkel Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary; Recurrent Mycosis Fungoides and Sezary Syndrome; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Nasal Type NK/T-Cell Lymphoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Recurrent Olfactory Neuroblastoma; Recurrent Oral Cavity Adenoid Cystic Carcinoma; Recurrent Oral Cavity Mucoepidermoid Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Oropharyngeal Undifferentiated Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Renal Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Recurrent Small Cell Lung Carcinoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Thyroid Gland Carcinoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Regional Adrenal Gland Pheochromocytoma; Regional Gastrointestinal Neuroendocrine Tumor G1; Small Intestinal Lymphoma; Somatostatin-Producing Neuroendocrine Tumor; Splenic Marginal Zone Lymphoma; Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary; Stage III Adult Soft Tissue Sarcoma; Stage III Bladder Cancer; Stage III Hypopharyngeal Squamous Cell Carcinoma; Stage III Laryngeal Squamous Cell Carcinoma; Stage III Laryngeal Verrucous Carcinoma; Stage III Lip and Oral Cavity Squamous Cell Carcinoma; Stage III Lip Basal Cell Carcinoma; Stage III Major Salivary Gland Carcinoma; Stage III Merkel Cell Carcinoma; Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage III Nasal Type NK/T-Cell Lymphoma; Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Stage III Nasopharyngeal Undifferentiated Carcinoma; Stage III Oral Cavity Adenoid Cystic Carcinoma; Stage III Oral Cavity Mucoepidermoid Carcinoma; Stage III Oral Cavity Verrucous Carcinoma; Stage III Oropharyngeal Squamous Cell Carcinoma; Stage III Oropharyngeal Undifferentiated Carcinoma; Stage III Pancreatic Cancer; Stage III Prostate Cancer; Stage III Renal Cell Cancer; Stage III Thyroid Gland Follicular Carcinoma; Stage III Thyroid Gland Papillary Carcinoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIA Rectal Cancer; Stage IIIA Skin Melanoma; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IIIB Rectal Cancer; Stage IIIB Skin Melanoma; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Rectal Cancer; Stage IIIC Skin Melanoma; Stage IV Adult Soft Tissue Sarcoma; Stage IV Bladder Cancer; Stage IV Breast Cancer; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Merkel Cell Carcinoma; Stage IV Nasal Type NK/T-Cell Lymphoma; Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Stage IV Nasopharyngeal Undifferentiated Carcinoma; Stage IV Non-Small Cell Lung Cancer; Stage IV Pancreatic Cancer; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Skin Melanoma; Stage IVA Basal Cell Lip Carcinoma; Stage IVA Colon Cancer; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Adenoid Cystic Carcinoma; Stage IVA Oral Cavity Mucoepidermoid Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVA Oropharyngeal Undifferentiated Carcinoma; Stage IVA Rectal Cancer; Stage IVA Thyroid Gland Follicular Carcinoma; Stage IVA Thyroid Gland Papillary Carcinoma; Stage IVB Basal Cell Lip Carcinoma; Stage IVB Colon Cancer; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Adenoid Cystic Carcinoma; Stage IVB Oral Cavity Mucoepidermoid Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVB Oropharyngeal Undifferentiated Carcinoma; Stage IVB Rectal Cancer; Stage IVB Thyroid Gland Follicular Carcinoma; Stage IVB Thyroid Gland Papillary Carcinoma; Stage IVC Basal Cell Lip Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Adenoid Cystic Carcinoma; Stage IVC Oral Cavity Mucoepidermoid Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Stage IVC Oropharyngeal Undifferentiated Carcinoma; Stage IVC Thyroid Gland Follicular Carcinoma; Stage IVC Thyroid Gland Papillary Carcinoma; T-Cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Thyroid Gland Medullary Carcinoma; Thyroid Gland Undifferentiated (Anaplastic) Carcinoma; Tongue Carcinoma; Waldenstrom Macroglobulinemia

 

Last Updated: 15 Dec 2014

Go to URL
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
 

Status: Recruiting

Condition Summary: 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer

 

Last Updated: 9 Oct 2014

Go to URL